Extended-release amantadine may improve levodopa dyskinesia control

VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. Amantadine...
Source: Family Practice News - Category: Primary Care Source Type: news